Press Release

2022 Sana Symposium to educate hundreds of clinicians on what’s here, what’s new, and what’s next in psychedelic therapies

October 12, 2022
Virtual event will feature promising results in psychedelic-assisted therapy to treat mental health disorders including major depression, addiction, anxiety, and PTSD, and highlight groundbreaking research and cutting-edge data.

MALVERN Pa., (October 12, 2022) — Now in its second year, the 2022 Sana Symposium will provide the latest research and updates in psychedelic-assisted therapy, a rapidly emerging field of practice to treat major depression, anxiety, addiction, PTSD, and other mental health disorders.

Sana Symposium is the official meeting of the Psychedelic Medicine Association. It will be held virtually October 13-15. The robust, three-day educational program will outline the best way for clinicians to stay up to date on research, receive training, and, once FDA approval is attained, implement new treatments into their practice to improve patient outcomes.

Key topics include psychopharmacology of psychedelics, regulatory updates across the nation, best practices in ketamine therapy (currently approved), and state-of-the-research updates across various substances including MDMA, psilocybin, LSD, and DMT. The featured session is “A Patient’s Lived Experience,” facilitated by Zach Skiles, Doctor of Clinical Psychology at the Portland, VA Medical Center-Vancouver in Vancouver, Wash.

“There was a time when treating intractable psychiatric conditions with the help of psychedelic medicines seemed far-fetched,” said Sana Symposium Co-Chairman Andrew Penn, RN, MS, NP, CNS, APRN-BC, clinical professor at the University of California, San Francisco. “But although it was once consigned to the fringes of psychiatric practice, psychedelic-assisted therapies are becoming more mainstream in the fields of psychiatry, psychotherapy, and addiction treatment.”

This field is evolving quickly, and Sana Symposium is a resource for clinicians to stay current on the latest clinical advances, research, and expert-guided strategies, said Co-Chairman Charles Raison, MD, Director of Clinical and Translational Research, Usona Institute; professor, Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison.

“The updates presented at Sana Symposium uncover promising results in using new treatment options for mental health disorders,” Raison said. “We want clinicians to gain the confidence and knowledge to effectively guide patients who are interested in psychedelic therapies and set the stage for a smooth transition of new treatment options into their practice. Ultimately, our goal is to improve outcomes for patients.”

Sana Symposium partners with nine world-renowned educators, practitioners, and research trailblazers in the field of psychedelics to make the conference an insightful, practical, and impactful educational experience. In addition to the symposium co-chairmen, steering committee members include:

  • Kwasi Adusei, DNP, PMHNP, co-founder of the Psychedelic Society of Western New York
  • Rick Doblin, PhD, founder and executive director, Multidisciplinary Association for Psychedelic Studies (MAPS)
  • Robin Carhart Harris, PhD, Ralph Metzner Professor of Neurology, Psychiatry & Behavioural Sciences, director of Psychedelics Division, Neuroscape, UCSF visiting professor, Centre for Psychedelic Research, Imperial College London
  • Rakesh Jain, MD, MPH, co-investigator, Psychedelics and Wellness Study (PAWS); clinical professor, Department of Psychiatry, Texas Tech Health Sciences Center School of Medicine
  • Saundra Jain, MA, PsyD, LPC, co-investigator, Psychedelics and Wellness Study (PAWS); adjunct clinical affiliate, University of Texas at Austin School of Nursing
  • Lynn Marie Morski, MD, Esq., president, Psychedelic Medicine Association; founder,; host, Plant Medicine podcast, medical director,
  • Rosalind Watts, PhD, clinical psychologist, founder, ACER Integration

In its inaugural year last year, more than 1,000 clinicians participated in this one-of-a-kind educational experience, uniting globally renowned experts across psychiatry, psychotherapy, and addiction treatment to provide diverse perspectives on the successful practice of psychedelic therapies.

Sana Symposium is designed and accredited for all members of mental health and addiction treatment teams and serves as the premier forum to connect members from three key fields of practice — psychiatry, psychotherapy, and addiction treatment. It is produced in partnership with Psych Congress, the nation’s largest independent psychiatry conference; Evolution of Psychotherapy, the world’s largest independent psychotherapy conference; and the Symposia on Addictive Disorders (formerly the National Conference on Addiction Disorders), the premier clinical addiction events.

For more information or to register, visit



HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare's most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America's largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit